09 Jun 2026 by admin in UncategorizedComments Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378
08 Jun 2026 by admin in UncategorizedComments OriCell’s GPC3 CAR-T Receives NMPA Clearance for Confirmatory Phase II Trial in Late-Line Advanced Hepatocellular Carcinoma
08 Jun 2026 by admin in UncategorizedComments China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
04 Jun 2026 by admin in UncategorizedComments Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors
01 Jun 2026 by admin in UncategorizedComments Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
29 May 2026 by admin in UncategorizedComments Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds
28 May 2026 by admin in UncategorizedComments Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study
28 May 2026 by admin in UncategorizedComments Zenas BioPharma Anounces Submision of Biologics License Aplication (BLA) to U.S. FDA for Obexelimab in IgG4-RD FDA for Obexelimab in IgG4-RD
18 May 2026 by admin in UncategorizedComments Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
06 May 2026 by admin in UncategorizedComments Alebund Pharmaceuticals Announces Completion of Patient Enrollment in Global Phase III Pivotal Multi-Regional Clinical Trial of AP301 for Hyperphosphatemia
